

KEDNAPA THAVORN, BPharm, MPharm, PhD

Clinical Epidemiology Program, Ottawa Hospital Research Institute,
The Ottawa Hospital - General Campus 501 Smyth Road, PO Box 201B, Ottawa, ON, K1H 8L6
P: 613-737-8899 x 72330 / F: 613-739-6938 Email: kthavorn@ohri.ca

EDUCATION

2014	Post-doctoral fellowship program (Applied Pharmacoeconomics); Li Ka Shing Knowledge Institute; St. Michael's Hospital, Ontario Post-doctoral fellowship program (Health Services Research); Institute of Health Policy, Management and Evaluation; University of Toronto
2012	Ph.D. (Health Services Research); Institute of Health Policy, Management and Evaluation; University of Toronto
2007	Master of Pharmacy (Pharmaceutical Sciences); Naresuan University, Phitsanulok, Thailand
2005	Bachelor of Pharmacy (Pharmacy); Faculty of Pharmacy; Chiang Mai University, Chiang Mai, Thailand

RECENT EMPLOYMENT HISTORY/AFFILIATIONS

Nov. 2021 – present	Visiting Professor; Faculty of Pharmacy, Chiang Mai University, Thailand
Sept. 2014 – present	Adjunct Scientist; ICES
Sept. 2014 – present	Assistant Professor; School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa
July 2014 – present	Senior Scientist/Health Economist; Ottawa Hospital Research Institute, Ottawa Hospital
Jan. 2013 – June 2014	Post-doctoral Fellow; University of Toronto, Toronto, Ontario
Nov. 2012 – June 2014	Post-doctoral Fellow; St. Michael's Hospital, Toronto, Ontario

SELECTED ACADEMIC HONOURS:

- Distinguished Alumni Awards, Faculty of Pharmacy, Chiang Mai University, Thailand, 2019
- The Best New Investigator Poster Presentation Award, International Society for Pharmacoeconomics and Outcomes Research, 2014
- Post-doctoral fellowship Award, University of Toronto, 2013/14
- The Best Presentation Award, HTAsiaLink Annual Conference, Thailand, 2012
- Post-doctoral fellowship Award, Li Ka Shing Knowledge Inst., St. Michael's Hospital, 2012-14
- Doctoral Completion Award, University of Toronto, 2011-2012
- Doctoral Fellowship Award, University of Toronto, 2010-2011
- Genesis Fellowship Award, CHSRF/CIHR, University of Toronto, 2007-2009

SELECTED RESEARCH FUNDING: (Total research funding = C\$97.4 million)

<u>Year</u>	<u>Source/Short title</u>	<u>Total Amount (C\$)</u>	<u>Role</u>
2021 - 2022	CIHR/ Understanding preferences for substance use health services for problematic alcohol use during the COVID-19 pandemic	\$262,235	Nominated PI
2021-2024	CIHR/ BIND Study: Assessing the indirect socio-economic burden of inherited neuromuscular diseases	\$449,031	Co-PI
2021-2024	CIHR/Prospective, multicentre, randomized, parallel-control, superiority study comparing administration of clotting factor concentrates with a standard massive hemorrhage protocol in severely bleeding trauma patients	\$1,021,275	Co-I
2021-2031	CIHR/ A prospective trial of radiation omission in patients with clinically node negative breast cancer and pathologic complete response after neoadjuvant	\$1,500,000	Co-I
2021-2024	CIHR/ Act-Cog: Online cognitive assessment in the Alteplase compared to Tenecteplase (Act) trial	\$330,000	Co-I
2020-2023	CIHR/Optimizing care journeys for adults with hip fractures	\$439,875	Co-I

2020-2023	CIHR/Building culturally safe cancer survivorship	\$738,225	Co-I
2019-2024	CIHR/Canadian Sepsis Research Network: Improving Care	\$5,700,000	Co-I
2019-2024	CIHR/The SAVER Trial	\$3,460,340	Co-I
2019-2024	CIHR/ Testing, Reaching the Undiagnosed and Linkages to Care: "REACHing" for Impact	\$5,999,995	Co-PI
2019-2024	CIHR/CIHR Centre for REACH in HIV/AIDS	\$4,808,015	Co-PI
2019-2024	CIHR/ The PATH Phase III Trial	\$1,507,050	Co-I
2019 - 2022	OICR/Using real world data to prioritize resource allocation for care and research for leukemia patients	\$284,955	Nominated PI
2019 - 2020	CIHR/ Evaluating Ontario's rapid access addiction medicine model of care to address the Canadian opioid crisis	\$96,962	Co-PI
2018-2023	Genome Canada/Microbiome-Based Medicine in IBD	\$9,111,566	Co-I

SELECTED PEER-REVIEWED PUBLICATIONS: Total number of papers in refereed journals: (N=188)

1. Nochaiwong S, Ruengorn C, Awiphan R, Chai-Adisaksopha C, Sood MM, Hutton B, **Thavorn K**. Use of Serotonin Reuptake Inhibitor Antidepressants Concomitant with Antithrombotic Therapy and the Risk of Bleeding Complications: A Systematic Review and Meta-Analysis. *Annals of Medicine*. 2021;54(1):80-97
2. Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Tovanabutra N, Chiewchanvit S, Hutton B, **Thavorn K**. Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response to H1-antihistamines on Health-Related Quality of Life: A Systematic Review and Network Meta-Analysis. *The Journal of Allergy and Clinical Immunology: In Practice*. 2021; 22:S2213-2198(21)01141-7.
3. Thavorn K, Kumar S*, Reis C, Lam J, Dobell G, Mulhall C, Grimshaw J, Ivers N. Audit Feedback Interventions to Address High-Risk Prescriptions in Long-Term Care Homes: A Costing Study and Return on Investment Analysis. *Implementation Sciences and Complications*. 2021; 28;2(1):125.
4. Kumar S*, Shen J, Grimes D, Mestre T, **Thavorn K**. Return on Investment Analysis for the Integrated Parkinson's Care Network: Lesson Learned from a Pilot Study. *Journal of Parkinson's Disease*. 2021. doi: 10.3233/JPD-212578.
5. Kimpton M*, Kumar S*, Wells PS, Coyle D, Carrier M, **Thavorn K**. Cost-utility analysis of apixaban compared to usual care for the primary thromboprophylaxis of cancer patients. *CMAJ*. 2021; 193 (40) E1551-E1560; DOI: <https://doi.org/10.1503/cmaj.210523>
6. Tu MM*, Clemons M, Stober C, Jeong A, Vandermeer L, Mates M, Blanchette P, Joy AA, Aseyev O, Pond G, Fergusson F, Ng T, Thavorn K. Cost-effectiveness analysis of 12- versus 4-weekly administration of bone-targeted agents in patients with bone metastases from breast and castration-resistant prostate cancer. *Current Oncology*. 2021; 13;28(3):1847-1856. doi: 10.3390/currenol28030171.
7. Kumar S, **Thavorn K**, van Katwyk S, Lasso A, Kilty S. Economic Evaluation of Endoscopic Polypectomy in Clinic Compared to Endoscopic Sinus Surgery: A Modelling Study. *Clin Otolaryngol*. 2020;45(4):477-485.
8. van Katwyk S, Augustine S, Thébaud B, **Thavorn K**. Lifetime patient outcomes and healthcare utilization for Bronchopulmonary dysplasia (BPD) and extreme preterm infants: a microsimulation study *BMC Pediatrics*. 2020;20(1):136. doi: 10.1186/s12887-020-02037-5.
9. van Katwyk S, Ferretti E, Kumar S, Hutton B, Harrold J, Walker M, Forster AJ, **Thavorn K**. Economic Analysis of Exclusive Human Milk Diets for High-Risk Neonates, a Canadian Hospital Perspective. *Breastfeeding Medicine*. Accepted March 14, 2020. In Press.
10. Isenberg SR, Tanuseputro P., Spruin S., Seow H., Goldman R, **Thavorn K**, Hsu AT. Cost-effectiveness of investment in end-of-life home care to enable death in community settings. *Medical Care*. Accepted January 5, 2020. In press.
11. Nithianandan H, **Thavorn K**, Banaz F, Macdonald K, Lasso A, Kilty S. Determining the hospital cost of anterior epistaxis treatment modalities at a Canadian tertiary care centre. *World Journal of Otorhinolaryngology - Head and Neck Surgery*. 2019.
12. Rockley M, Kobewka D, Kunkel E, Nagpal S, McIsaac D, **Thavorn K**, Forster A. Characteristics of High-cost Inpatients with Peripheral Arterial Disease. *Journal of Vascular Surgery*. 2020: pii: S0741-5214(19)32570-4.
13. Stewart D, Blair MD, Awan A, **Thavorn K**. Optimal frequency of scans for patients on cancer therapies: A

- population kinetics assessment. *Cancer Medicine*. 2019. 8(16):6871-6886. doi: 10.1002/cam4.2571.
14. Arroxelass M, Clemons M, Van Katwyk S, Carol S, Robertson S, Vandermeer L, Fergusson D, **Thavorn K**. Cost analysis of using Magee scores as a surrogate of Oncotype Dx® for adjuvant treatment decisions in women with early breast cancer. *Journal of Evaluation in Clinical Practice*. 2019. 2019;1–4.
 15. Black CD, **Thavorn K**, Coyle D, Bjerre L. The health system costs of potentially inappropriate prescribing: a population-based, retrospective cohort study using linked health administrative databases in Ontario, Canada. *Pharmacoeconomic Open*. 2019. doi: 10.1007/s41669-019-0143-2.
 16. Petrosyan Y, **Thavorn K**, Maclure M, Smith G, McIsaac D, Schramm D, Moloo H, Preston R, Forster AJ. Long-term health outcomes and health system costs associated with surgical site infections: a retrospective cohort study. *Annals of Surgery*. 2019. doi:
 17. van Katwyk S, **Thavorn K**, Coyle D, Moloo H, Forster AJ, Jackson T, Schramm D. The return of investment of hospital-based surgical quality improvement programs in reducing surgical site infection at a Canadian tertiary-care hospital. *Infection Control & Hospital Epidemiology*. 2018;1-8.
 18. Robin P, Kumar S, Saluan PY, Le Roux PY, Couturaud F, Planquette B, Merah A, Roy PM, **Thavorn K**, Le Gal G. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. *Thrombosis Research*. 2018; 171:97-102.
 19. Le A, **Thavorn K**, Lasso A, Kilty SJ. Economic Evaluation of Floseal Compared to Nasal Packing for the Management of Anterior Epistaxis. *The Laryngoscope*. 2018 Jan 4.
 20. Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoon K, Chaisai C, Noppakun K, **Thavorn K**. The association between proton pump inhibitors use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. *Nephrology Dialysis Transplantation* 2018; 33(2):331-342.
 21. Huang A, **Thavorn K**, Van Katwyk S, MacDonald P, Lapner P. Double-Row Arthroscopic Rotator Cuff Repair Is More Cost-Effective Than Single-Row Repair. *The Journal of Bone & Joint Surgery*. 2017. 99(20):1730-1736.
 22. Tricco A, Cogo E, Thomas S, Hamid J, Striffler L, Khan P, Sibley K, Robson R, MacDonald H, Riva J, **Thavorn K**, Wilson C, Holroyd-Leduc J, Kerr G, Feldman F, Majumdar S, Jaglal S, Hui W, Straus S. Comparative Efficacy of Preventing Falls in Older Adults: A systematic review and network meta-analysis. *JAMA*. 2017. 318(17):1687-1699.
 23. **Thavorn K**, Maxwell C, Grunier A, Bronskil S, Kone A, Petrosyan Y, Qing Y, Wodchis W. The Effect of Socio-demographic Factors on the Association between Multimorbidity and Healthcare Costs: A Population-based Study. *BMJ Open*. 2017;7(10): e017264.
 24. van Katwyk S, Jin YP, Trope GE, Buys Y, Masucci L, Wedge R, Flanagan J, Brent M, El-Defrawy, Tu HA, **Thavorn K**. Cost-utility analysis of extending public health insurance coverage to include diabetic retinopathy screening by optometrists. *Value in Health*. 2017 ;20(8):1034-1040.
 25. Van Katwyk S, Coyle D, Cooper C, Pussegoda K, Cameron C, Skidmore B, Brenner S, **Thavorn K**. Transient Elastography in Diagnosing Liver Fibrosis in Patients: A Systematic Review of Economic Evaluations. *Liver International*. 2017. 37(6):851-861.
 26. **Thavorn K**, Coyle D, Hoch J, Vandermeer L, Mazzarello S, Wang Z, Dranitsaris G, Fergusson D, Clemons M. A cost-utility analysis of Risk Model-Guided versus Physician's Choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net-benefit regression approach. *Supportive Care in Cancer*. 2017 Mar 9.
 27. Chen I, **Thavorn K**, Shen M, Goddard Y, Yong P, MacRae GS, Nishi C, Matar A, Allaire C. Hospital-associated costs of chronic pelvic pain in Canada: a population-based descriptive study. *Journal of Obstetrics and Gynaecology Canada*. 2017 Mar;39(3):174-180.
 28. Yong JH, **Thavorn K**, Hoch JS, Mamdani M, Thorpe KE, Dorian P, Sharma M, Laupacis A, Gladstone DJ, EMBRACE Steering Committee. Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke. *Stroke*. 2016; 47(9): 2380-5.
 29. **Thavorn K**, Wang Z, Fergusson D, van Katwyk S, Arnaout A, Clemons M. The Cost Implications of Unwarranted Imaging for Distant Metastases in Women with Early-Stage Breast Cancer in Ontario. *Current Oncology* 2016; 23(Suppl 1): S52-5.